Tag Archives: biopharmaceutical

Sanofi gains full global rights to a promising antibody for inflammatory disorders with the acquisition of Kymab

(PRESS RELEASE) PARIS/ CAMBRIDGE, 11-Jan-2021 — /EuropaWire/ — French multinational pharmaceutical company Sanofi to acquire Kymab, a clinical-stage biopharmaceutical company developing fully human monoclonal antibodies with a focus on immune-mediated diseases and immuno-oncology therapeutics. The agreement includes an upfront payment … Read the full press release

Zeta Group and Siemens to work together for digital transformation of pharmaceutical processes

Strategic partnership for digital transformation of pharmaceutical processes Operational usage of digital plant data New Smart Engineering Services (SES) New modules improve integration in the value chain (PRESS RELEASE) NUREMBERG/ LIEBOCH/ GRAZ, 3-Nov-2020 — /EuropaWire/ — Siemens and Zeta Gmbh … Read the full press release

ESMO Virtual Congress 2020: Libtayo positive pivotal data offer hope for the treatment of advanced basal cell carcinoma, a difficult-to-treat cancer

Libtayo is the first investigational medicine to show a clinical benefit in advanced basal cell carcinoma following treatment with a hedgehog inhibitor in a prospective trial 31% objective response rate seen in trial patients, and an estimated 85% of responses … Read the full press release

Sanofi tender offer for Principia Biopharma outstanding shares, August 28 – September 25, 2020

(PRESS RELEASE) PARIS, 28-Aug-2020 — /EuropaWire/ — French multinational pharmaceutical company Sanofi announces its intention to commence a tender offer (the “Offer”) to acquire all of the outstanding shares of common stock of Principia Biopharma Inc. for $100 per share … Read the full press release

Immune-mediated diseases biopharmaceutical Principia Biopharma Inc. acquired by Sanofi for approximately EUR 3.1 billion ($3.68 billion)

Further strengthens core R&D areas of autoimmune and allergic diseases Provides full control of brain-penetrant BTK inhibitor SAR442168 in multiple sclerosis (MS), making commercialization more efficient and eliminating future royalty payments Allows expansion of SAR442168 development program into other central … Read the full press release

Alfa Laval introduces unique separator system for safer and more efficient biopharmaceutical processing

(PRESS RELEASE) LUND, 14-Apr-2020 — /EuropaWire/ — Alfa Laval announces the launch of a unique separator system, Alfa Laval CultureOne™, for single-use processing in the biopharmaceutical industry. With Alfa Laval CultureOne™ system the risk of cross-contamination is eliminated with the … Read the full press release

PDA GMP for APIs Education Webinar Now an “ICH Recognised Training Programme”

PDA met ICH’s twelve eligibility criteria to gain recognition (PRESS RELEASE) BERLIN, 22-Nov-2019 — /EuropaWire/ — The Parenteral Drug Association (PDA) is proud to announce that its “ICH Q7 GMP for APIs” online training module is now endorsed by the … Read the full press release

ILC Dover to Open New Production Facility in Blarney, Ireland for Added Capabilities, Capacity and Jobs

Expansion positions ILC as leading single use powder handling solutions provider to the global pharma & biopharma market FREDERICA, DE, USA, 01-Nov-2018 — /EuropaWire/ — ILC Dover, a global leader in flexible containment solutions for the pharmaceutical and biopharmaceutical industry … Read the full press release

SGS to expand its biopharmaceutical testing capabilities in Geneva with a new 200m2 laboratory

GENEVA, 04-Sep-2018 — /EuropaWire/ — SGS, a leading bio/pharmaceutical analytical and bioanalytical contract solutions provider, today announced it is expanding its biopharmaceutical testing capabilities in Geneva, Switzerland with a new 200m2 laboratory. The laboratory will be equipped with a number of … Read the full press release

John C. Reed, M.D. Ph.D. to succeed Elias Zerhouni, M.D. as Head of Global Research and Development at Sanofi

PARIS, 25-Apr-2018 — /EuropaWire/ — Elias Zerhouni, M.D., Head of Global Research and Development will retire from Sanofi on June 30th, 2018, after more than 9 years of distinguished service with the company. He will be succeeded in the post … Read the full press release

Sanofi acquires Bioverativ Inc., a biopharmaceutical company focused on therapies for hemophilia and other rare blood disorders

Expands Sanofi’s presence in specialty care and strengthens leadership in rare diseases  Adds leader in the growing hemophilia market and provides platform for expansion in other rare blood disorders  Drives meaningful shareholder value with ROIC expected to exceed cost of … Read the full press release

200 healthcare decision-makers gather to address the looming challenges of cost, access and sustainability in the coming wave of high-value medicines

LONDON, 01-Dec-2017 — /EuropaWire/ — On December 5-6, 2017, 200 high-level experts from government, academia, biopharmaceutical developers and patient organisations convene in London (UK) to address the mounting challenge of accessibility and patient access to high-value, high-cost medical therapies. The … Read the full press release

SAVOR-TIMI-53 cardiovascular outcomes trial of ONGLYZA® results announced by AstraZeneca and Bristol-Myers Squibb

20-6-2013 — /europawire.eu/ — AstraZeneca and Bristol-Myers Squibb announced today top-line results of the Phase IV SAVOR-TIMI-53 (Saxagliptin Assessment of Vascular Outcomes Recorded in Patients with Diabetes Mellitus) clinical trial of Onglyza ® (saxagliptin). In this study of adult patients with … Read the full press release